Iododoxorubicin in Advanced Breast Cancer
Author Information
Author(s): C.J. Twelves, N.A. Dobbs, M.A. Lawrence, A.J. Ramirez, M. Summerhayes, M.A. Richards, K.E. Towlson, R.D. Rubens
Primary Institution: Imperial Cancer Research Fund Clinical Oncology Unit, Division of Oncology, and Division of Psychiatry, United Medical and Dental Schools, Guy's Hospital
Hypothesis
This phase II study aimed to appraise fully the clinical activity, toxicity, pharmacology, and effect on quality of life of iododoxorubicin in patients with advanced breast cancer.
Conclusion
Iododoxorubicin has limited activity in metastatic breast cancer and does not significantly improve quality of life.
Supporting Evidence
- The response rate was 14%, with no complete responses and only two partial responses.
- Median time to progression was 3.5 months and median survival was 10.2 months.
- Quality of life assessments showed little evidence of benefit during treatment.
Takeaway
The study tested a new cancer drug called iododoxorubicin on women with advanced breast cancer, but it didn't work very well and didn't make them feel better.
Methodology
Patients received iododoxorubicin as an intravenous injection every 3 weeks for a maximum of six cycles, and various assessments were made regarding clinical activity, toxicity, pharmacology, and quality of life.
Limitations
The response rate was lower than expected, and the study was limited by the small sample size.
Participant Demographics
Women aged 18-75 with histologically confirmed breast cancer and measurable metastatic or locally recurrent disease.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI 4-40%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website